Why It Matters

Mindful Choices for ADHD wants to influenced federal ADHD treatment policy.

Mindful Choices will likely try to influence debates around the Safe Step Act, which restricts insurance step-therapy protocols; the Telehealth Coverage Act, extending remote ADHD care access; and the Patients’ Right to Know Their Medication Act, supporting medication education.

By the Numbers

Mindful Choices for ADHD registered on June 30, 2024, retaining Venn Strategies LLC, a major firm founded in 2003 with over 100 clients and more than $100 million in cumulative lobbying fees.

Lobbying team:

• Madison P. West: Former congressional staffer with nearly three years of Hill experience, previously with Rep. Dina Titus (D-NV) and Senate Special Committee on Aging.

• Jakara Mariah Eason: Healthcare lobbyist also representing Tris Pharma Inc. on ADHD treatment policy and the American Diabetes Association.

• Stephanie Epstein Silverman: Veteran lobbyist with 22 years of experience in healthcare and pharmaceutical policy, representing clients including Eli Lilly & Co. and Regeneron Pharmaceuticals Inc.

The Agenda

Mindful Choices for ADHD is lobbying on "policy discussions and education related to appropriate use of ADHD treatment."

Broader Context

Congress is actively addressing ADHD treatment barriers amid rising diagnoses and persistent medication shortages. The policy environment reflects competing pressures: urgent treatment access needs versus regulatory tightening following high-profile telehealth fraud cases and new DEA rules governing controlled substance prescribing online. Tris Pharma Inc. and the Association for Behavioral Health and Wellness are already actively lobbying on overlapping issues, creating a crowded advocacy landscape where "appropriate use" messaging is becoming central to policy debates.

Competitive Landscape

Mindful Choices enters an active advocacy environment. Tris Pharma Inc. reported $200,000 in quarterly lobbying expenditures for ADHD treatment policy. The Association for Behavioral Health and Wellness lobbies on telehealth prescribing rules, while Qbtech AB focuses on Medicaid coverage of ADHD diagnostics. Notably, Mindful Choices shares both lobbying firm and lobbyist Eason with Tris Pharma, suggesting potential coordination on core ADHD policy issues.

The Bottom Line

Mindful Choices for ADHD enters federal advocacy as ADHD diagnoses surge and medication access becomes increasingly contentious. The organization’s "appropriate use" messaging arrives amid severe stimulant shortages, fraud-driven regulatory tightening, and competing congressional efforts to expand telehealth access while preventing abuse. With Venn Strategies LLC—already representing ADHD manufacturer Tris Pharma Inc.—Mindful Choices now has a platform to influence ongoing debates around key ADHD legislation, reflecting rising congressional attention to this policy space despite significant existing stakeholder competition.